Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12882-12894

  Armitage, Andrew E ^a   Deforche, Koen ^b   Welch, John J ^c   Van Laethem, Kristel ^b   Camacho, Ricardo ^b,d   Rambaut, Andrew ^e   Iversen, Astrid K N ^a,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; DEAMINASE; PROTEASOME; VIF PROTEIN; VIRUS PROTEIN; VIRUS RNA; APOBEC3 PROTEIN, HUMAN; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CYTOSINE DEAMINASE; POL PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA STRAND; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; RNA SEQUENCE; SOMATIC HYPERMUTATION; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MUTATION RATE; POINT MUTATION; VIROLOGY;

CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION RATE; POINT MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; SELECTION, GENETIC;

EID: 84907983225     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01460-14     Document Type: Article

References (100)

1. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489. http://dx.doi.org/10.1126/science.7824947.
2. Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5:52-61. http://dx.doi.org/10.1038/nrg1246.
3. Malim MH. 2009. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:675-687. http://dx.doi.org/10.1098/rstb.2008.0185.
4. Chaipan C, Smith JL, Hu WS, Pathak VK. 2013. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87:444-453. http://dx.doi.org/10.1128/JVI.00676-12.
5. Hache G, Mansky LM, Harris RS. 2006. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8:148-157.
6. Harris RS. 2008. Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26:1089-1090. http://dx.doi.org/10.1038/nbt1008-1089.
7. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
8. Malim MH. 2006. Natural resistance to HIV infection: the Vif-APOBEC interaction. C. R. Biol. 329:871-875. http://dx.doi.org/10.1016/j.crvi.2006.01.012.
9. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
10. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. http://dx.doi.org /10.1371/journal.ppat.0010006.
11. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003 The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038 /nature01707.
12. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK. 2008. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERVK( HML2) sequences. J. Virol. 82:8743-8761. http://dx.doi.org/10.1128 /JVI.00584-08.
13. da Costa KS, Leal E, dos Santos AM, Lima e Lima AH, Alves CN, Lameira J. 2014. Structural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloB. PLoS One 9:e89116. http: //dx.doi.org/10.1371/journal.pone.0089116.
14. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, Yu Y, Zang Y, Yang M, Huang Z. 2014. Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505:229-233. http://dx.doi.org/10.1038/nature12884.
15. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
16. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
17. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc.M313093200.
18. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
19. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
20. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
21. Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, Gerstoft J, Fugger L, McMichael A, Rambaut A, Iversen AK. 2012. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genetics 8:e1002550. http://dx.doi.org/10.1371/journal.pgen.1002550.
22. Deforche K, Camacho R, Laethem KV, Shapiro B, Moreau Y, Rambaut A, Vandamme AM, Lemey P. 2007. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J. Comput. Biol. 14:1105-1114. http://dx.doi.org/10.1089/cmb.2007.0073.
23. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. 2001. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 29:296-299 http://dx.doi.org/10.1093/nar/29.1.296.
24. Snoeck J, Riva C, Steegen K, Schrooten Y, Maes B, Vergne L, Van Laethem K, Peeters M, Vandamme AM. 2005. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J. Virol. Methods 128:47-53. http://dx.doi.org/10.1016/j.jviromet.2005.04.001.
25. Brennan CA, Yamaguchi J, Devare SG, Foster GA, Stramer SL. 2010. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drugresistant strains: 2005 through 2007. Transfusion 50:2707-2712. http://dx.doi.org/10.1111/j.1537-2995.2010.02767.x.
26. Swofford DL. 2003. PAUP*: phylogenetic analysis using parsimony (*and other methods), 4.0 b10 ed. Sinauer Associates, Sunderland, MA.
27. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. 2005. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV Med. 13:125-131.
28. Lemey P, Derdelinckx I, Rambaut A, Van Laethem K, Dumont S, Vermeulen S, Van Wijngaerden E, Vandamme AM. 2005. Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J. Virol. 79:11981-11989. http://dx.doi.org/10.1128 /JVI.79.18.11981-11989.2005.
29. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557. http://dx.doi.org/10.1073/pnas.0802203105.
30. Berkhout B, de Ronde A. 2004. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18:1861-1863 http://dx.doi.org/10.1097/00002030-200409030-00022.
31. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, Hui H. 2004. Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J. Virol. 78: 2426-2433. http://dx.doi.org/10.1128/JVI.78.5.2426-2433.2004.
32. Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
33. Shpaer EG, Mullins JI. 1990. Selection against CpG dinucleotides in lentiviral genes: a possible role of methylation in regulation of viral expression. Nucleic Acids Res. 18:5793-5797. http://dx.doi.org/10.1093/nar/18.19.5793.
34. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396. http://dx.doi.org/10.1016/j.cub.2004.06.057.
35. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442. http://dx.doi.org/10.1038/nsmb758.
36. Bourara K, Liegler TJ, Grant RM. 2007. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 3:1477-1485. http://dx.doi.org/10.1371/journal.ppat.0030153.
37. Harari A, Ooms M, Mulder LC, Simon V. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303. http://dx.doi.org/10.1128/JVI.01665-08.
38. Koning FA, Goujon C, Bauby H, Malim MH. 2011. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J. Virol. 85:13448-13452. http://dx.doi.org/10.1128/JVI.00775-11.
39. Love RP, Xu H, Chelico L. 2012. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 287:30812-30822 http://dx.doi.org/10.1074/jbc.M112.393181.
40. Marin M, Golem S, Rose KM, Kozak SL, Kabat D. 2008. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82:987-998. http://dx.doi.org/10.1128/JVI.01078-07.
41. Refsland EW, Hultquist JF, Harris RS. 2012. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8:e1002800. http://dx.doi.org/10.1371/journal.ppat.1002800.
42. Wang X, Abudu A, Son S, Dang Y, Venta PJ, Zheng YH. 2011. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85:3142-3152. http://dx.doi.org/10.1128/JVI.02049-10.
43. Langlois MA, Beale RC, Conticello SG, Neuberger MS. 2005. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33:1913-1923. http: //dx.doi.org/10.1093/nar/gki343.
44. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391. http://dx.doi.org/10.1016/j.cub.2004.06.050.
45. McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi D, Asahchop EL, Brenner BG, Harrigan PR, Xu H, Wainberg MA. 2013. Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrob. Agents Chemother. 57:4681-4688. http://dx.doi.org/10.1128/AAC.01029-13.
46. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, Munson PJ, Wahl SM. 2007. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110:393-400. http://dx.doi.org /10.1182/blood-2006-10-051763.
47. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, Bouaziz S, Muriaux D, Darlix JL, Cimarelli A. 2011. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 7:e1002221. http://dx.doi.org/10.1371/journal.ppat.1002221.
48. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K. 2007. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4:61. http://dx.doi.org/10.1186/1742-4690-4-61.
49. An P, Johnson R, Phair J, Kirk GD, Yu XF, Donfield S, Buchbinder S, Goedert JJ, Winkler CA. 2009. APOBEC3B deletion and risk of HIV-1 acquisition. J. Infect. Dis. 200:1054-1058. http://dx.doi.org/10.1086 /605644.
50. Imahashi M, Izumi T, Watanabe D, Imamura J, Matsuoka K, Ode H, Masaoka T, Sato K, Kaneko N, Ichikawa S, Koyanagi Y, Takaori-Kondo A, Utsumi M, Yokomaku Y, Shirasaka T, Sugiura W, Iwatani Y, Naoe T. 2014. Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. PLoS One 9:e92861. http://dx.doi.org/10.1371/journal.pone.0092861.
51. Doehle BP, Schafer A, Cullen BR. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288. http://dx.doi.org/10.1016/j.virol.2005.06.005.
52. Dang Y, Wang X, Esselman WJ, Zheng YH. 2006. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80:10522-10533. http://dx.doi.org/10.1128/JVI.01123-06.
53. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234. http://dx.doi.org/10.1128/JVI.05238-11.
54. Wang X, Abudu A, Son S, Dang Y, Venta PJ, Zheng YH. 2011. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85:3142-3152. http://dx.doi.org/10.1128/JVI.02049-10.
55. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5:e1000414. http://dx.doi.org/10.1371 /journal.ppat.1000414.
56. Ebrahimi D, Anwar F, Davenport MP. 2011. APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. J. Virol. 85:9139-9146. http://dx.doi.org/10.1128/JVI.00658-11.
57. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. 2005. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 79:1975-1980. http://dx.doi.org/10.1128/JVI.79.3.1975-1980.2005.
58. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, Simon A, Katlama C, Simon V, Calvez V, Marcelin AG. 2010. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 24:2313-2321. http://dx.doi.org/10.1097/QAD.0b013e32833e515a.
59. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, Wolinsky SM. 2010. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 84:10402-10405. http://dx.doi.org/10.1128/JVI.01223-10.
60. Mulder LC, Harari A, Simon V. 2008. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105:5501-5506. http: //dx.doi.org/10.1073/pnas.0710190105.
61. Sadler HA, Stenglein MD, Harris RS, Mansky LM. 2010. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84:7396-7404. http://dx.doi.org/10.1128/JVI.00056-10.
62. Hazen R, Lanier ER. 2003. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J. Acquir. Immune Defic. Syndr. 32:255-258. http://dx.doi.org/10.1097/00126334-200303010-00003.
63. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-1051. http://dx.doi.org/10.1038/12487.
64. Turriziani O, Schuetz JD, Focher F, Scagnolari C, Sampath J, Adachi M, Bambacioni F, Riva E, Antonelli G. 2002. Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem. J. 368:325-332. http://dx.doi.org/10.1042/BJ20020494.
65. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P. 2000. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U. S. A. 97:7476-7481. http://dx.doi.org/10.1073/pnas.120159197.
66. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. 2003. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int. Immunopharmacol. 3:879-887. http://dx.doi.org/10.1016/S1567-5769(03)00076-6.
67. Martinez MA, Vartanian JP, Wain-Hobson S. 1994. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. U. S. A. 91:11787-11791 http://dx.doi.org/10.1073/pnas.91.25.11787.
68. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, Kao S, Walker RC, Jr, Hirsch V, Strebel K. 2010. Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84:11067-11075. http://dx.doi.org/10.1128/JVI.01249-10.
69. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, Harari A, Kunz A, Simon V. 2010. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 84:9613-9617. http: //dx.doi.org/10.1128/JVI.02630-09.
70. Dang Y, Abudu A, Son S, Harjes E, Spearman P, Matsuo H, Zheng YH. 2011 Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J. Virol. 85:5691-5695. http://dx.doi.org/10.1128/JVI.00243-11.
71. Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. 2014. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426:1220-1245. http://dx.doi.org/10.1016/j.jmb.2013.10.033.
72. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
73. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374-2381. http://dx.doi.org/10.1128/JVI.01898-08.
74. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
75. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. 2009. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83: 1992-2003. http://dx.doi.org/10.1128/JVI.01621-08.
76. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. 2008. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 3:e3963. http://dx.doi.org/10.1371/journal.pone.0003963.
77. Albin JS, Hache G, Hultquist JF, Brown WL, Harris RS. 2010. Longterm restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 84:10209-10219. http: //dx.doi.org/10.1128/JVI.00632-10.
78. Albin JS, LaRue RS, Weaver JA, Brown WL, Shindo K, Harjes E, Matsuo H, Harris RS. 2010. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285:40785-40792. http: //dx.doi.org/10.1074/jbc.M110.173161.
79. Han Y, Wang X, Dang Y, Zheng YH. 2008. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog. 4:e1000095. http://dx.doi.org/10.1371/journal.ppat.1000095.
80. Ara A, Love R, Chelico L. 2014. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog. 10:e1004024. http://dx.doi.org/10.1371/journal.ppat.1004024.
81. Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM. 2013. Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology 443:306-312. http://dx.doi.org/10.1016/j.virol.2013.05.019.
82. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. 2005. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79:11513-11516. http://dx.doi.org/10.1128/JVI.79.17.11513-11516.2005.
83. Kourteva Y, De Pasquale M, Allos T, McMunn C, D' Aquila RT. 2012. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology 430:1-9. http://dx.doi.org/10.1016/j.virol.2012.03.018.
84. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, Kanki PJ. 2008 Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J. Infect. Dis. 198:486-492. http://dx.doi.org/10.1086/590212.
85. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G. 2009. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6:23. http://dx.doi.org /10.1186/1742-4690-6-23.
86. Zhao M, Geng W, Jiang Y, Han X, Cui H, Dai D, Bao M, Pan Y, Wang Y, Zhang X, Zhang M, Qi G, Shang H. 2010. The associations of hA3G and hA3B mRNA levels with HIV disease progression among HIVinfected individuals of China. J. Acquir. Immune Defic. Syndr. 53(Suppl 1):S4-S9. http://dx.doi.org/10.1097/QAI.0b013e3181c7d349.
87. Mous K, Jennes W, Camara M, Seydi M, Daneau G, Mboup S, Kestens L, Van Ostade X. 2012. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals. PLoS One 7:e33934. http://dx.doi.org/10.1371 /journal.pone.0033934.
88. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485. http://dx.doi.org/10.1128/JVI.01089-09.
89. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010 Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284. http://dx.doi.org/10.1093/nar/gkq174.
90. Mbisa JL, Bu W, Pathak VK. 2010. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84:5250-5259. http://dx.doi.org/10.1128/JVI.02358-09.
91. Ebrahimi D, Anwar F, Davenport MP. 2012. APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology 9:113. http://dx.doi.org/10.1186/1742-4690-9-113.
92. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. 2002. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.DNACell Biol. 21:671-678. http://dx.doi.org/10.1089/104454902760330219.
93. Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, Khatri A, Strick D, Phillips MN, Cohen GB, Islam SA, Kalams SA, Brander C, Goulder PJ, Rosenberg ES, Walker BD. 2001. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167:2743-2752. http://dx.doi.org/10.4049/jimmunol.167.5.2743.
94. Chen J, Hong K, Jia M, Liu H, Zhang Y, Liu S, Zhang X, Zhao H, Peng H, Ma P, Xing H, Ruan Y, Williams KL, Yu XG, Altfeld M, Walker BD, Shao Y. 2007. Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B=/C recombinant (CRF07_BC). Retrovirology 4:62. http://dx.doi.org/10.1186/1742-4690-4-62.
95. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53. http://dx.doi.org/10.1038/nm1520.
96. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung' u T, Marlink R, Lee TH, Essex M. 2002. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 76:10155-10168. http://dx.doi.org/10.1128/JVI.76.20.10155-10168.2002.
97. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, Matthews P, Payne R, Rolland M, Raugi DN, Maust BS, Learn GH, Nickle DC, Coovadia H, Ndung' u T, Frahm N, Brander C, Walker BD, Goulder PJ, Bhattacharya T, Heckerman DE, Korber BT, Mullins JI. 2008. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J. Virol. 82:6434-6446. http://dx.doi.org/10.1128/JVI.02455-07.
98. Yu XG, Lichterfeld M, Addo MM, Altfeld M. 2005. Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? Curr. Med. Chem. 12:741-747. http://dx.doi.org/10.2174/0929867053202205.
99. Lisovsky I, Schader SM, Sloan RD, Oliveira M, Coutsinos D, Bernard NF, Wainberg MA. 2013. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction. Intervirology 56:258-264. http://dx.doi.org/10.1159/000348513.
100. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A. 2010. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 207:39-49. http://dx.doi.org/10.1084/jem.20091933.